Studies have identified that inhibitors of the PTEN/Akt/GSK3β signaling cascade and regulation of β-catenin act as potential agents to effectively target cancer stem cells and tumorigenic cancer cells [3, 4]. The gene discussed is AKT1; the disease is cancer.